Phase II Study to Evaluate The Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma.

Trial Profile

Phase II Study to Evaluate The Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Rilotumumab (Primary) ; Bevacizumab
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Dec 2015 Primary end point was changed from Radiological response rates (Time frame 6 months) to Radiographic Response (Time frame 2 years)
    • 09 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 12 Mar 2015 Planned End Date changed from 1 Feb 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top